EDEvangeline Ann Daniel

Evangeline Ann Daniel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Evangeline Ann Daniel has a total of 41 co-authors. Here are the top co-authors by number of shared publications:

  • Luke Elizabeth Hanna

    Department of Virology and Biotechnology, ICMR-National Institute for Research in Tuberculosis, Chetpet, Chennai, 600031, India

    3 shared publications
  • Amita Gupta

    Division of Infectious Diseases, School of Medicine, Johns Hopkins University , Baltimore, Maryland

    2 shared publications
  • Amsaveni Sivaprakasam

    National Institute for Research in Tuberculosis, Indian Council of Medical Research (ICMR)

    2 shared publications
  • Brindha Bhanu

    National Institute for Research in Tuberculosis, Indian Council of Medical Research (ICMR)

    2 shared publications
  • Afrânio L Kritski

    Programa Acadêmico de Tuberculose da Faculdade de Medicina, Universidade Federal do Rio de Janeiro , Rio de Janeiro

    1 shared publication
  • Alice M S Andrade

    Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative , Salvador

    1 shared publication

Latest Publications

  • Predictive Markers of Incident Tuberculosis in Close Contacts in Brazil and India

    by Betânia M F Nogueira, Francys Rangel, Alice M S Andrade, Evangeline Ann Daniel, Marina C Figueiredo, Cody Staats, Valeria C Rolla, Afrânio L Kritski, Marcelo Cordeiro-Santos, Amita Gupta, et al.

    There are insufficient predictors of progression to tuberculosis among contacts. A case-control study within RePORT-Brazil matched 20 QuantiFERON-positive progressors and 40 nonprogressors by sex, age, and exposure duration. Twentynine cytokines were measured using a Luminex assay with QuantiFERON-TB Gold Plus supernatants collected at baseline and evaluated using machine learning for tuberculosis prediction. The same markers were evaluated in 8 QuantiFERON-positive progressors and 12 nonprogressors from India. Interleukin 8, interleukin 10, and CCL3 levels predicted incident tuberculosis (area under the receiver operating characteristic curve, 0.75) in 2 years with sensitivity and specificity >80%, in both cohorts. This signature predicted tuberculosis progression in close contacts meeting World Health Organization goals.


  • Open Access

    Predictive metabolite signatures for risk of progression to active TB from QuantiFERON supernatants of household contacts of TB patients

    by Evangeline Ann Daniel, Shubham Upadhyay, Murugesan Selvachithiram, Sathyamurthi Pattabiraman, Brindha Bhanu, Amsaveni Sivaprakasam, Vandana Kulkarni, Rajesh Karyakarte, Sanjay Gaikwad, Mandar Paradkar, et al.

    The identification of individuals with the greatest risk of progression to active tuberculosis (TB) disease from the huge reservoir of Mycobacterium tuberculosis (Mtb) infected individuals continues to remain an arduous ascent in the global effort to control TB. In a two-year prospective study, we analysed metabolic profiles in the unstimulated and TB antigen stimulated QuantiFERON supernatants of 14 healthy household contacts (HHCs) who progressed to TB disease (Progressors) and 14 HHCs who remained healthy (Non-Progressors). We identified 21 significantly dysregulated metabolites in the TB antigen-stimulated QuantiFERON supernatants of Progressors, of which the combination of Malic acid and N-Arachidonoylglycine had maximum AUC of 0.99. Eighteen significantly dysregulated metabolites were identified in the unstimulated QuantiFERON supernatants of Progressors, among which the combination of Orotic acid and the phosphatidylcholines PC (O-34:1), PC (O-18:1(9Z)/16:0), PC (O-18:1(11Z)/16:0) had the maximum AUC of 0.98. Most of the dysregulated metabolites belonged to the pathways of fatty acid metabolism, lipid metabolism and nitric oxide metabolism. Validation of these metabolic signatures in large, diverse cohorts would pave way for the development of a robust test that can identify individuals at high risk of TB for targetted intervention of TB disease.


  • QuantiFERON Supernatant-Based Host Biomarkers Predicting Progression to Active Tuberculosis Disease Among Household Contacts of Tuberculosis Patients

    by Evangeline Ann Daniel, Kannan Thiruvengadam, Anuradha Rajamanickam, Padmapriyadarsini Chandrasekaran, Sathyamurthi Pattabiraman, Brindha Bhanu, Amsaveni Sivaprakasam, Mandar Paradkar, Vandana Kulkarni, Rajesh Karyakarte, et al.

    Background: The positive predictive value of tuberculin skin test and current generation interferon gamma release assays are very low leading to high numbers needed to treat. Therefore, it is critical to identify new biomarkers with high predictive accuracy to identify individuals bearing high risk of progression to active tuberculosis (TB). Methods: We used stored QuantiFERON supernatants from 14 household contacts of index TB patients who developed incident active TB during a 2-year follow-up and 20 age and sex-matched non-progressors. The supernatants were tested for an expanded panel of 45 cytokines, chemokines, and growth factors using the Luminex Multiplex Array kit. Results: We found significant differences in the levels of TB-antigen induced production of several analytes between progressors and non-progressors. Dominance analysis identified 15 key predictive biomarkers based on relative percentage importance. Principal component analysis revealed that these biomarkers could robustly distinguish between the 2 groups. Receiver operating characteristic analysis identified interferon-γ inducible protein (IP)-10, chemokine ligand (CCL)19, interferon (IFN)-γ, interleukin (IL)-1ra, CCL3, and granulocyte-macrophage colony-stimulating factor (GM-CSF) as the most promising predictive markers, with area under the curve (AUC) ≥90. IP-10/CCL19 ratio exhibited maximum sensitivity and specificity (100%) for predicting progression. Through Classification and Regression Tree analysis, a cutoff of 0.24 for IP-10/CCL19 ratio was found to be ideal for predicting short-term risk of progression to TB disease with a positive predictive value of 100 (95% confidence interval [CI] 85.8–100). Conclusions: The biomarkers identified in this study will pave way for the development of a more accurate test that can identify individuals at high risk for immediate progression to TB disease for targeted intervention.


  • Open Access

    MicroRNAs as Diagnostic Biomarkers for Tuberculosis: A Systematic Review and Meta- Analysis

    by Evangeline Ann Daniel, Balakumaran Sathiyamani, Kannan Thiruvengadam, Sandhya Vivekanandan, Hemanathan Vembuli, Luke Elizabeth Hanna

    The early diagnosis of tuberculosis with novel non-sputum-based biomarkers is of high priority in End TB strategy. MicroRNAs are significant regulators of TB pathogenesis and their differential expression pattern among healthy, latent, and active TB population has revealed their potentiality as biomarkers in recent studies. We performed systematic review and meta-analysis on the role of host miRNAs in TB diagnosis. PubMed, Ovid, and Cochrane databases were searched to retrieve published literature. Relevant studies were screened, and their quality was assessed using STARD guidelines and QUADAS-2 tool. Heterogeneity of studies and overall pooled results of sensitivity, specificity, and DOR were determined by forest plots. Out of 447 studies, 21 were included for qualitative analysis and eight for meta-analysis. Among these, miR-31 had the maximum diagnostic accuracy, with a sensitivity of 96% (89·7-98·5), specificity of 89% (81·2-93·8), and DOR of 345·9 (90·2-1326·3), meeting the minimal target product profile (TPP) for TB diagnostics. Funding Information: This work was supported by the Department of Science and Technology (DST), DST-INSPIRE fellowship. Declaration of Interests: The authors declare no conflicts of interest.